MAP2K1 and ovarian carcinoma: These data from both combination trials indicate that the dual pharmacological inhibition of CRL4 and MEK1/2 outperforms KH‐4‐43 and trametinib as single agents and that these inhibitors cooperate to enhance each other's antitumor activity and may provide benefits in both cisplatin‐sensitive and cisplatin‐resistant ovarian cancer contexts.